Leadership Team

Sandeep Bajaj, MD—FACS Founder and CEO

Practice/Group:

Florida Cardiology, P.A.

Dr. Bajaj is the President of the Florida Heart Association, an Organization committed to providing high quality & greater access and lower costs to the consumer. He has served in official capacity in the American College of Cardiology and Florida Medical Association. He is the President of Fl Cardiology, PA .

Education & Fellowships:
Medical School: Jawaharial Institute of Post-Graduate Medical Education -Dhanvantari Nagar, Pondicherry, India 

Residency: University of Medicine & Dentistry of New Jersey – Newark, NJ  

Fellowship: Medical College of Virginia – Richmond, VA/Washington Adventist Hospital – Takoma Park, MD

Board Certifications
Interventional Cardiology
Cardiovascular Disease
Internal Medicine

Professional Memberships
Florida Medical Association (FMA)
American College of Cardiology (ACC)
American College of Physicians (ACP)
American College of Chest Physicians (ACCP)
American Heart Association (AHA)

Hospitals
Advent Health

Areas of Expertise & Interest
Invasive and Interventional Cardiology including Angioplasty, Peripheral Vascular Angiography and Interventions; Diagnostic Heart Catheterizations, Percutaneous Coronary Interventions, Atherectomies and Stents; Temporary Pacemaker Insertions; Cardiovascular CT and Nuclear Cardiology

Languages spoken
English, Hindi

Offices

Address: 483 N. Semoran Blvd Ste 102, Winter Park, FL 32792
Office Phone Number: 407-645-1847
Fax Phone Number: 321-274-0246

Address: 7440 Red Bug Lake Road, Oviedo, FL 32765
Office Phone Number: 407-971-0000
Fax Phone Number: 407-971-0008

Address: 1307 S International Pkwy, Suite 2071 Lake Mary, FL 32746
Office Phone Number: 407-638-9000
Fax Phone Number: 407-878-7009

Address: 515 W State Rd 434, Suite 301 Longwood, FL 32750
Office Phone Number: 407-638-9000
Fax Phone Number: 407-878-7009

ASHISH GUPTA, MD, PHD

Dr. Ashish Gupta, MD, PhD is an Interventional Cardiologist and Endovascular disease specialist. He is a Diplomate of American Board of Internal Medicine with board certification in Internal Medicine, Cardiovascular Disease and Interventional Cardiology. Dr. Gupta obtained his PhD in Experimental Medicine from prestigious Postgraduate Institute of Medical Education and Research in India. He did his post doctoral training at University of Colorado Health Science Center, Denver, Colorado, UT Health Science Center at Houston and University of Texas Medical Branch, Galveston, TX. Dr. Gupta obtained his medical school training from Saba University in Netherlands-Antilles. He did his residency and fellowship training from University of Florida at Gainesville, Florida. Dr. Gupta is dedicated towards providing comprehensive cardiovascular care to his patients. His clinical interests include medical and endovascular management of peripheral arterial disease with focus on limb salvage and preventing amputations. He offers endovenous options for venous disease. His other clinical interests include management of acute and chronic angina, cardiovascular disease risk modification, resistant hypertension, dyslipidemia, pulmonary hypertension, acute and chronic venothromboembolic disease (DVT and PE), intra and extravascular imaging, transthoracic and transesophageal echo, implantable loop recorders. Dr. Gupta is engaged as principal or sub clinical investigator in several national and international trials. He has published in several international peer-reviewed journals. Dr. Gupta is recipient of several awards and honors including prestigious Alpha Omega Alpha Medical Society honor award, teaching awards from residents and medical students at University of Florida. He has been a regular faculty at National Cardiovascular Horizons Meeting at Orlando for last several years. He was also invited as a faculty for International Complex Cardiovascular transcatheter therapeutics C3 conference in Orlando in 2019.

KARAN G. REDDY, MD, FACC, FACP

Dr. Karan G. Reddy is Board Certified in Internal Medicine and Cardiovascular Medicine, Interventional Cardiology, CardiovascularCT, and Nuclear Cardiology.

After finishing his Cardiology Fellowship training, Dr. Reddy joined Florida Cardiology in 1992.

Areas of Expertise & Interest:

Invasive and Interventional Cardiology including angioplasty stents and permanent pacemakers. Peripheral Vascular Angiography and Interventions, including Atherectomy, Laser, Angioplasty and Stents etc. Diagnosis and Management of Vein Disorders (Vein Stenting, Vein Ablation, Phlebectomy and Sclerotherapy).

Clinical, Noninvasive, Echocardiography, Cardiovascular CT and Nuclear Cardiology, Preventative Cardiology including Lipid Disorders. Dr. Reddy has been an investigator for several research trials for new drugs and new devices.

Awards

Dr.Reddy was awarded 2015 Values Award by Florida Hospital. This award is for Integrity, Compassion, Balance, Excellence, Stewardship and Teamwork. He was one of only five physicians from about 2,500 physicians chosen for this award.

Marc Steven Penn, M.D., Ph.D., FACC

Dr. Marc Penn is a cardiologist, Director of Research and Program Director for the Cardiovascular Medicine Fellowship at Summa Health Heart and Vascular Institute (Akron, OH). He is a Professor of Medicine and Integrative Medical Sciences at Northeast Ohio Medical University (Rootstown, OH). From 2000-11 Dr. Penn was a cardiologist at the Cleveland Clinic where he served as the Director of the Coronary Intensive Care Unit, Director of the Experimental Animal Laboratory, Director of the Bakken Heart-Brain Institute, and the Founding Director of the Center for Cardiovascular Cell Therapy. Dr. Penn completed his undergraduate and postgraduate work at Case Western Reserve University completing a Ph.D. in Biomedical Engineering in 1989 and Doctor of Medicine in 1994. He completed his Internal Medicine training at University Hospitals of Cleveland (1994-97) and his Cardiovascular Medicine Fellowship at Cleveland Clinic (1997-2000). He is board certified in Internal Medicine and Cardiovascular Medicine. During his training he received numerous awards including the 2000 Joseph Cash Memorial Prize for Clinical Outcomes Research and the 1999 Irvine H. Page Young Investigator award for Atherosclerosis Research presented by the National American Heart Association. He has adjunct appointments at Case Western Reserve University in Biomedical Engineering and in the Bioengineering Center at Cleveland State University. Dr. Penn’s research has led to several discoveries in the field of cardiovascular medicine including in diagnostics, strategies to optimize gene and stem cell therapy for regeneration of myocardial tissue, as well as neuromodulation of cardiac function. Dr. Penn has organized and lectured at international symposia and conferences, and is author or co-author of hundreds of articles, abstracts, book chapters and books on a wide range of topics in basic and translation science, and clinical medicine. Dr. Penn is an active inventor, serial entrepreneur and internationally recognized as an expert in translating basic science research to clinical populations. He has generated intellectual property in the fields of diagnostics, biologics and devices that has been licensed by numerous companies, having authored dozens of U.S. and international patent applications. He is the founder of Juventas Therapeutics, Inc. (Cleveland, OH), a regenerative medicine company founded on his intellectual property based on novel fundamental concepts of endogenous stem cell mediated tissue repair pioneered by his group. As CMO of Juventas Therapeutics, Inc. (2007-2016) he designed and executed the Phase II studies STOP-CLI, STOP-HF, RETRO-HF and designed the STOP-PAD. His SDF-1 technology was optioned by Astellas Pharmaceutical in December of 2018. He was co-founder and CMO of Cleveland Heart Lab, Inc. (Cleveland, OH), a revenue stage diagnostic company based on biomarkers associated with coronary artery disease, myocardial infarction, and other inflammatory diseases. Quest Diagnostics acquired Cleveland Heart Lab in December of 2017. He is a Senior Advisor to Quest Diagnostics and serves as the Medical Director for the Quest Diagnostics Center of Excellence of Cardiometabolic Testing at Cleveland Heart Lab. He is the Chief Medical Officer of Diasome, Inc. (Cleveland, OH), Cambridge Science, Inc. (Boston, MA) and Keystone Bio, Inc. (St. Louis, MO). From 2016-2019 as CEO of Black Beret Life Sciences, LLC (Houston, TX) where he oversaw the life science investments and led the executive teams of numerous companies including Tissue Genesis, LLC, (Honolulu, HI), Advanced Regen Medical Technologies, LLC, (Newark NJ), and the regenerative medicine treatment center, Okyanos (Freeport Bahamas), as well as the sugar replacement Sola (Houston, TX). He is an advisor and board member of numerous companies. He was the PI of the Athersys MultiStem in AMI Phase I and II trials (Cleveland, OH), and served on the SMAB of NeuroTronik, Inc. (Raleigh, NC). He was a Venture Partner with Oakwood Medical Investors (2004-2010, St. Louis, MO), a member of the Advisory Board of Frantz Medical Ventures (2004-08, New York, NY), and a Clinical Partner with Foundation Medical Partners (2009-11, New Canaan, CT) where he represented the interests of the Cleveland Clinic. He served on the DSMB of the NIH Heart Failure Network since its inception. He was chair of the BOD of Cour Pharma (2007-2010, Kalamazoo, MI), and served on the BOD of CardioVIP (2012-2014, Houston, TX) and Non- Invasix (2016-2019 Houston, TX). He serves on the BOD of Rhythm Therapeutics (Chicago, IL), Keystone Bio (St. Louis, MO) and Diasome (Cleveland, OH). From 2008-10 Dr. Penn was the Senior Medical Director for Emerging Businesses at Cleveland Clinic. He was the 2006 Innovator of the Year, and in 2011 recognized as one of the top 50 doctors in the history of the Cleveland Clinic (MedCity News).

Richard Cairl, PHD

Prior to joining FACS in 2011, Dr. Cairl held several research and academic positions, with publications in the field of gerontology and long term care. His long-standing dedication to the elderly is evidenced not only by his academic publications, but as well his contributions as a consultant to the development of numerous community based programs for the elderly, and the administrative and clinical operations of several major Medicare Advantage Organizations. As VP of Clinical Program Development for FACS, Dr. Cairl has taken the lead in the development, coordination, and implementation of several clinical programs and service (e.g., Annual Wellness Visit Program; Commercial Health Risk Assessment Program; Chronic Care Management Program; ER Diversion Program; Transitions of Care Program; Comprehensive Risk Medical Assessment and Risk Stratification Program; MACRA/MIPS Compliance Program) each dedicated to the success of FACS Medicare and commercial ACO efforts. In addition to these efforts, Dr. Cairl has provided continuous substantive input in a team-based development, implementation, and on-going operation of the robust Health Information Exchange (HIE) platform that enables FACS providers to work together in a clinically integrated network, leading to improved operational efficiencies, the provision of timely and meaningful clinical integration and continuity of care, and overall healthcare cost savings.